Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06710847 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

A Phase 1 study of Solid Tumor and Endometrial Cancer, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 1
Development phase
14
Enrollment target
20
Study locations

NCT06710847 is a Phase 1 study of Solid Tumor and Endometrial Cancer that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 14 participants, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06710847, a Phase 1 study of Solid Tumor and Endometrial Cancer, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
14 participants
Enrollment target
20
Study locations

Study Summary

Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK4418959 alone or in combination with a PD-1 inhibitor agent can decrease tumor size, is safe, well-tolerated, and how amounts of the study drug decrease in the body over time.

Conditions Studied

Solid Tumor Endometrial Cancer Colon Cancer Rectal Cancer Neoplasms, Colorectal

Interventions

  • DRUG GSK4418959
  • BIOLOGICAL PD-1 inhibitor

Study Locations (20)

Other

  • GSK Investigational Site - Brussels
  • GSK Investigational Site - Ghent
  • GSK Investigational Site - Leuven
  • GSK Investigational Site - Chiba
  • GSK Investigational Site - Shizuoka
  • GSK Investigational Site - Tokyo
  • GSK Investigational Site - Tokyo
  • GSK Investigational Site - Amsterdam
  • GSK Investigational Site - Daegu
  • GSK Investigational Site - Gyeonggi-do
  • GSK Investigational Site - Seoul
  • GSK Investigational Site - Barcelona
  • GSK Investigational Site - Barcelona

Pennsylvania

  • GSK Investigational Site - Philadelphia
  • GSK Investigational Site - Philadelphia

California

  • GSK Investigational Site - Los Angeles

Colorado

  • GSK Investigational Site - Denver

Michigan

  • GSK Investigational Site - Detroit

New York

  • GSK Investigational Site - New York

Victoria

  • GSK Investigational Site - Melbourne

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2024-12-13
Est. Completion 2026-06-22
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06710847

The ClinicalTrials.gov registry entry for NCT06710847 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (94% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which GSK4418959 is the first listed.

NCT06710847 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Pennsylvania, California.

Frequently Asked Questions

What is clinical trial NCT06710847 about?

NCT06710847 is a clinical study titled "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors". Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK4418959 alone or in combination with a PD-1 i...

What is the current status of trial NCT06710847?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2024-12-13. Estimated completion is 2026-06-22.

What conditions does trial NCT06710847 study?

This clinical trial studies the following conditions: Solid Tumor, Endometrial Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Colorectal.

What interventions are being tested in trial NCT06710847?

The interventions under investigation include: GSK4418959 (DRUG), PD-1 inhibitor (BIOLOGICAL).

Who is sponsoring clinical trial NCT06710847?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06710847 being conducted?

This trial has 20 study locations across California, Colorado, Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor

All registered trials for this condition

Endometrial Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.